Compare Amgen, Inc. (AMGN) vs Weibo Corp (WB) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amgen, Inc. vs Weibo Corp — how do they compare? Amgen, Inc. trades at $363.55 (market cap $196.12B), while Weibo Corp trades at $7.7 (market cap $1.89B). The key difference: Amgen, Inc. is far larger — about 103.8× Weibo Corp's market cap, and Weibo Corp pays the higher dividend (7.89%). Which is the better fit depends on your goals.
| AMGN | WB | |
|---|---|---|
Market Cap | $196.12B | $1.89B |
Sector | Health | Media |
52-Week High | $388.16 | $12.83 |
52-Week Low | $271.18 | $7.20 |
Enterprise Value | $241.41B | $1.16B |
Dividend Yield | 2.77% | 7.89% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
Weibo (WB) trades at $7.72 with a bullish technical signal and strong valuation metrics, including a P/E of 5.41 and P/B of 0.49. Recent earnings missed estimates in three consecutive quarters, but the company maintains robust profitability with a 21.15% net income margin. A dividend of $0.61 was declared for H1 2026, supporting shareholder returns amid competitive pressures.
The stock presents value with deep undervaluation relative to cash flows and balance sheet strength, though user engagement challenges and rivalry from Douyin pose growth risks. Analyst consensus is mixed with 45% buy ratings, highlighting potential upside if execution improves, but investors face headwinds from China's regulatory environment and advertising volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Weibo Corp
Weibo is the largest social media platform in China. As of 2020, Weibo had 521 million monthly active users and 225 million daily active users, many of whom are drawn there by the millions of key opinion leaders in entertainment, sports, and business circles. Sina is the major shareholder, holding 44.7% of shares and with 70.8% voting power.
Read more on WB →
